Lepr(db/db) Mice with senescence marker protein-30 knockout (Lepr(db/db)Smp30(Y/-)) exhibit increases in small dense-LDL and severe fatty liver despite being fed a standard diet

PLoS One. 2013 Jun 3;8(6):e65698. doi: 10.1371/journal.pone.0065698. Print 2013.

Abstract

Background/aims: The senescence marker protein-30 (SMP30) is a 34 kDa protein originally identified in rat liver that shows decreased levels with age. Several functional studies using SMP30 knockout (Smp30(Y/-) ) mice established that SMP30 functions as an antioxidant and protects against apoptosis. To address the potential role of SMP30 in nonalcoholic fatty liver disease (NAFLD) pathogenesis, we established Smp30(Y/-) mice on a Lepr(db/db) background (Lepr(db/db)Smp30(Y/-) mice). RESEARCH DESIGN/PRINCIPAL FINDINGS: Male Lepr(db/db)Smp30(Y/-) mice were fed a standard diet (340 kcal/100 g, fat 5.6%) for 16 weeks whereupon the lipid/lipoprotein profiles, hepatic expression of genes related to lipid metabolism and endoplasmic reticulum stress markers were analyzed by HPLC, quantitative RT-PCR and western blotting, respectively. Changes in the liver at a histological level were also investigated. The amount of SMP30 mRNA and protein in livers was decreased in Lepr(db/db)Smp30(Y/+) mice compared with Lepr(db/+)Smp30(Y/+) mice. Compared with Lepr(db/db)Smp30(Y/+) mice, 24 week old Lepr(db/db)Smp30(Y/-) mice showed: i) increased small dense LDL-cho and decreased HDL-cho levels; ii) fatty liver accompanied by numerous inflammatory cells and increased oxidative stress; iii) decreased mRNA expression of genes involved in fatty acid oxidation (PPARα) and lipoprotein uptake (LDLR and VLDLR) but increased CD36 levels; and iv) increased endoplasmic reticulum stress.

Conclusion: Our data strongly suggest that SMP30 is closely associated with NAFLD pathogenesis, and might be a possible therapeutic target for NAFLD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CD36 Antigens / genetics
  • CD36 Antigens / metabolism
  • Calcium-Binding Proteins / deficiency
  • Calcium-Binding Proteins / genetics*
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Diet, High-Fat / adverse effects
  • Dietary Fats / administration & dosage
  • Endoplasmic Reticulum Stress / genetics*
  • Gene Expression Regulation
  • Intracellular Signaling Peptides and Proteins / deficiency
  • Intracellular Signaling Peptides and Proteins / genetics*
  • Lipid Metabolism
  • Liver / metabolism*
  • Liver / pathology
  • Male
  • Mice
  • Mice, Transgenic
  • Non-alcoholic Fatty Liver Disease / etiology
  • Non-alcoholic Fatty Liver Disease / genetics*
  • Non-alcoholic Fatty Liver Disease / metabolism
  • Non-alcoholic Fatty Liver Disease / pathology*
  • PPAR alpha / genetics
  • PPAR alpha / metabolism
  • Receptors, LDL / genetics
  • Receptors, LDL / metabolism
  • Receptors, Leptin / genetics
  • Receptors, Leptin / metabolism
  • Severity of Illness Index
  • Signal Transduction

Substances

  • CD36 Antigens
  • Calcium-Binding Proteins
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Dietary Fats
  • Intracellular Signaling Peptides and Proteins
  • PPAR alpha
  • Receptors, LDL
  • Receptors, Leptin
  • Rgn protein, mouse
  • VLDL receptor
  • leptin receptor, mouse

Grants and funding

This study is supported by the Japan Society for the Promotion of Science (http://www.jsps.go.jp/english/e-grants/index.html) KAKENHI Grant Number 24380073 (A. Ishigami), 23590441 (N. Maruyama), 23790122 (Y. Kondo) and 23591317 (G. Hasegawa). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.